The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the chief technology officer at Amgen, a leading independent biotech company ...

The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new biotechnology methods instead to spur innovation in the pharmaceutical ...

FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter,” early stage biotechs are rewriting their financing strategies around ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...

CEP certification confirms Brains Bio’s naturally-derived CBD pharmaceutical ingredient meets European Pharmacopoeia ...

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.